Acorda Therapeutics® is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Acorda’s marketed products include Zanaflex Capsules® (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) tablets. Zanaflex Capsules and Zanaflex are short-acting drugs approved for the management of spasticity. Because of the short duration of effect, treatment should be reserved for those daily activities and times when relief of spasticity is most important. The most frequent adverse events with these products are dry mouth, sedation, asthenia, and dizziness, and are most often considered mild to moderate. For full prescribing information click here.

The Company also has a product in clinical development - Fampridine-SR. In June 2008, Acorda announced positive results from its second positive Phase 3 clinical trial of Fampridine-SR on walking ability in people with MS. On May 6, 2009 Acorda announced that the U.S. Food and Drug Administration (FDA) accepted the Fampridine-SR New Drug Application (NDA) for filing, assigning Priority Review and a Prescription Drug User Fee Act (PDUFA) date of October 22, 2009. The PDUFA date is the target date for the FDA to complete its review of the Fampridine-SR NDA. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain through its preclinical pipeline.